Skip to main content
Caplight Logo









TJ Biopharma

TJ Biopharma

Private
HangzhouHealthcare & Life Scienceshttps://tjbio.com/

Last Round

Series C

Extension

Sep 30, 2025

Total Funding Raised

$116M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

TJ Biopharma is a biotechnology company that develops, manufactures, and commercializes innovative biologics for autoimmune diseases, immuno-oncology, and metabolic disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Clean Manufacturing

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Data as a Service

AI Layer

Non-AI

Keywords

biologicsmonoclonal antibodybispecific antibodyCDMOcontract manufacturingbiotechdrug discoveryimmuno-oncologyautoimmune diseaseGMP manufacturingbiopharmametabolic disordersdrug licensingantibody engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TJ Biopharma Comparables

Compare TJ Biopharma with similar companies based on industry and business-model similarity.

TJ Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Genexine Inc
77%
Alphamab Oncology
77%
Innovent Biologics
74%

TJ Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionSep 30, 2025
Series C ExtensionFeb 7, 2024
Series BJul 16, 2022
Series ASep 15, 2020

TJ Biopharma Investors

Notable investors and investment history

TJ Biopharma investors
InvestorRounds
Oriental Fortune CapitalSeries C Extension
CCIC CapitalSeries C Extension
Hangzhou Industrial & Commercial TrustSeries A, Series B
Viva BiotechSeries A, Series B
Value Partners GroupSeries A, Series B
Yijing CapitalSeries C Extension
Zhejiang Haibang Private Equity Fund Management Co., Ltd.Series A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Grew 38% QoQ, from 8 to 11 employees.

  • Sep 30, 2025

    $84M round led by CCIC Capital.

TJ Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TJ Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TJ Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Employee Range13
Year Founded2019
Last FundingSep 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?